Thom T, Haase N, Rosamond W. et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85–151. [PubMed: 16407573]
Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of Stroke: A Risk Profile From the Framingham Study. Stroke. 1991;22:312–18. [PubMed: 2003301]
U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136(2):157–60. [PubMed: 11790071]
Ridker PM, Cook NR, Lee IM. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304. [PubMed: 15753114]
Whitlock EP, Lin JS, Chou R, Shekelle P, Robinson KA. Using existing systematic reviews in complex systematic reviews. Ann Intern Med. 2008;148(10):776–82. [PubMed: 18490690]
Harris R, Atkins D, Berg AO, Best D, et al. US Preventive Services Task Force Procedure manual Rockville, MD: Agency for Healthcare Research and Quality; 2001.
Harris RP, Helfand M, Woolf SH. et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(Suppl 3):21–35. [PubMed: 11306229]
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Jama. 2006;295(3):306–13. [PubMed: 16418466]
Peto R, Gray R, Collins R, Whealey K, Hennekens C, Jamrozik K. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296(6618):313–6. [PMC free article: PMC2544821] [PubMed: 3125882]
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321(3):129–35. [PubMed: 2664509]
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351(9098):233–41. [PubMed: 9457092]
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–62. [PubMed: 9635947]
de Gaetano G. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357(9250):89–95. [PubMed: 11197445]
Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J, Warnold I. HOT Study Group. et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20(11):2301–7. [PubMed: 12409970]
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264–72. [PubMed: 14633812]